

# MaÅ,gorzata TÅ,ustochowicz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3130746/publications.pdf>

Version: 2024-02-01

11  
papers

96  
citations

1684188

5  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

234  
citing authors

#	ARTICLE	IF	CITATIONS
1	Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.	2.2	38
2	Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland. <i>Reumatologia</i> , 2016, 54, 278-284.	1.1	9
3	A dose-dependent beneficial effect of methotrexate on the risk of interstitial lung disease in rheumatoid arthritis patients. <i>PLoS ONE</i> , 2021, 16, e0250339.	2.5	9
4	Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009–2014. <i>Archives of Medical Science</i> , 2018, 14, 569-571.	0.9	7
5	Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study. <i>Reumatologia</i> , 2018, 56, 140-148.	1.1	7
6	Common atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration. <i>Rheumatology International</i> , 2019, 39, 327-336.	3.0	7
7	Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008–2012. <i>Reumatologia</i> , 2015, 2, 79-86.	1.1	4
8	Treat-to-target therapy does not prevent excessive progression of carotid intima media thickness during the first year of therapy in early rheumatoid arthritis. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2016, 1, 42-49.	1.0	4
9	Trends in psoriatic arthritis epidemiology in Poland. <i>Rheumatology International</i> , 2021, 41, 139-145.	3.0	4
10	Quality of life and clinical outcomes in Polish patients with high activity rheumatoid arthritis treated with leflunomide (Arava®) in Therapeutic Program: A retrospective analysis of data from the PLUS study. <i>Advances in Clinical and Experimental Medicine</i> , 2019, 28, 1545-1553.	1.4	4
11	Prevalence of axial spondyloarthritis in Poland. <i>Rheumatology International</i> , 2020, 40, 323-330.	3.0	3